1.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2009-03, NCT00868569
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2009-04, NCT00874406
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: Oxali04882, NCT01023633
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PROFUSE-2011, NCT01468623
|
|
6.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEMCAD-1006, NCT01493713
|
|
7.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2012-03, NCT01564810
|
|
8.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25753, NCT01588990
|
|
9.
|
Phase: Phase IV Type: Supportive care Status: Approved-not yet active Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 0869-225, MK-0869-225, NCT01636947
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000470411, FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000595050, FRE-FNCLCC- ACCORD-17-0707, EU-20848, NCT00861094
|
|
12.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FDRT-002, NCT01064999
|
|
13.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: JBZ-EnRoute+, EnRoute+, EUDRACT-2010-018612-32, EU-21016, NCT01097265
|
|
14.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-DLC-001, NCT01197560
|
|
15.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: BREC-AGC, NCT01206218
|
|
16.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FLOT4, NCT01216644
|
|
17.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 0291-1crgi09, NCT01348217
|
|
18.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N1048, N1048, NCT01515787
|
|
19.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: TOTTG030103, NCT01516944
|
|
20.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EGC-0254/87/2011, UML-EGC-2011, NCT01523015
|
|
21.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-1207, 2012-002317-18, NCT01646554
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: FFCD 2000 – 05, CET 815, NCT00126256
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HEPATICA, NCT00394992
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-CHRONICLE, CRUK-BRD/05/132, EU-20679, ISRCTN59865116, CTA21106/0016/001, EUDRACT-2004-001484-21, NCT00427713
|